The DOI matches its Crossref record; 218 of the 220 references it cites were found in a registry or an index.
Guidelines to cell engineering for monoclonal antibody production
Open accessAbstract
Monoclonal antibodies (mAbs) are currently used for many diagnostic and therapeutic applications. The high demand for these biopharmaceuticals has led to the development of large-scale manufacturing processes, with productivity improvements being mainly achieved by optimization of bioreactor systems. However, more recently, the early steps of production, previous to bioreactor culture, have been presented as alternative areas where productivity enhancements can be achieved. Thus, this review describes the progress made for the improvement of productivity in mammalian expression systems for the high production of mAbs. Advances in the development of mAb-producing cell lines are being made, particularly regarding expression vector design and methods used for transfection, with the intent to create a reproducible methodology. Selection of the most suitable clones is also a critical step that can be improved, by including variables other than the expression level, which is still the common practice. Furthermore, strategies of cell engineering, although still mostly based on trial-and-error experimentation and not in standard protocols, hold great interest to improve cell growth and productivity, as well as product quality in the future. Improvements of the initial steps of the production process would not only result in cells with higher expression ability, but would also speed-up the process development.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Yet, it is ideal for high throughput screening for hits identification and very helpful for early stage product characterization (Ozturk and Hu, 2005;Rosser et al., 2005;Rita Costa et al., 2010).”
From Therapeutic glycoprotein production in mammalian cells (2017) · cites this paper as Rita Costa et al., 2010
In the citing paper
“By skipping the lengthy selection process for the cells that have integrated the plasmid within their genome, transient transfection is much faster (Rita Costa et al., 2010).”
From Therapeutic glycoprotein production in mammalian cells (2017) · cites this paper as Rita Costa et al., 2010
In the citing paper
“For stable expression, a gene marker is usually integrated in the expression plasmid along with the cDNA encoding the gene of interest, conferring a selective advantage to the cells that integrate the plasmid into their genome (Rita Costa et al., 2010).”
From Therapeutic glycoprotein production in mammalian cells (2017) · cites this paper as Rita Costa et al., 2010
Citations
Cites
Continuous cultures of fused cells secreting antibody of predefined specificity
Köhler, G., & Milstein, C. (1975) · Nature · doi:10.1038/256495a0 · Cited by 17,200
A new technique for the assay of infectivity of human adenovirus 5 DNA
Graham, F. L., & van der Eb, A. J. (1973) · Virology · doi:10.1016/0042-6822(73)90341-3 · Cited by 9,302
Boussif, O., Lezoualc’h, F., Zanta, M. A., Djavaheri‐Mergny, M., Scherman, D., DEMENEIX, B. A., & Behr, J. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.16.7297 · Cited by 6,256
Kozak, M. (1986) · Cell · doi:10.1016/0092-8674(86)90762-2 · Cited by 4,741
Danial, N. N., & Korsmeyer, S. J. (2004) · Cell · doi:10.1016/s0092-8674(04)00046-7 · Cited by 4,651
Freshney, R. I. (2005) · Wiley eBooks · doi:10.1002/9780470649367 · Cited by 3,904
Transcriptional Activation by Tetracyclines in Mammalian Cells
Gossen, M., Freundlieb, S., Bender, G., Müller, G., Hillen, W., & Bujard, H. (1995) · Science · doi:10.1126/science.7792603 · Cited by 2,488 · cited 1×
“[68], the tetracycline (tet) [69,70], the streptogramin [71] and the ecdysone [72] systems.”
BackgroundSV40-transformed simian cells support the replication of early SV40 mutants
Gluzman, Y. (1981) · Cell · doi:10.1016/0092-8674(81)90282-8 · Cited by 2,343
Production of recombinant protein therapeutics in cultivated mammalian cells
Wurm, F. M. (2004) · Nature Biotechnology · doi:10.1038/nbt1026 · Cited by 2,032
Shinkawa, T., Nakamura, K., Yamane, N., Shoji-Hosaka, E., Kanda, Y., Sakurada, M., Uchida, K., Anazawa, H., Satoh, M., Yamasaki, M., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210665200 · Cited by 1,413
Cited by
Sorted by citations
Trends in Upstream and Downstream Process Development for Antibody Manufacturing
Gronemeyer, P., Ditz, R., & Strube, J. (2014) · Bioengineering · doi:10.3390/bioengineering1040188 · Cited by 347
Therapeutic glycoprotein production in mammalian cells
Lalonde, M.-E., & Durocher, Y. (2017) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2017.04.028 · Cited by 296
Perfusion mammalian cell culture for recombinant protein manufacturing – A critical review
Bielser, J., Wolf, M., Souquet, J., Broly, H., & Morbidelli, M. (2018) · Biotechnology Advances · doi:10.1016/j.biotechadv.2018.04.011 · Cited by 284
Advances in the production and downstream processing of antibodies
Chon, J. H., & Zarbis‐Papastoitsis, G. (2011) · New Biotechnology · doi:10.1016/j.nbt.2011.03.015 · Cited by 230
Gene Expression in Mammalian Cells and its Applications
Khan, K. H. (2013) · Europe PMC (PubMed Central) · doi:10.5681/apb.2013.042 · Cited by 166
Metadata
- Authors
- Rita Costa, A., Elisa Rodrigues, M., Henriques, M., Azeredo, J., & Oliveira, R.
- Affiliations
- Institute for Biotechnology and Bioengineering (PT)
- Corresponding author
- Henriques, Mariana
- Venue
- European Journal of Pharmaceutics and Biopharmaceutics
- Publisher
- Elsevier BV
- Published
- 2010-02
- Volume
- 74
- Issue
- 2
- Pages
- 127-138
- ISSN
- 0939-6411 (ISSN-L)
- OpenAlex
- W2108422551
- Cited by
- 178
- References
- 220
- Citations by year
- 2026: 2 · 2025: 8 · 2024: 10 · 2023: 12 · 2022: 8 · 2021: 14 · 2020: 11 · 2019: 9 · 2018: 13 · 2017: 17 · 2016: 8 · 2015: 10 · 2014: 15 · 2013: 20 · 2012: 10
- FWCI
- 2.80
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- Locations
- European Journal of Pharmaceutics and Biopharmaceutics (publishedVersion)
- PubMed (publishedVersion)
- RepositóriUM (Universidade do Minho) (submittedVersion, other-oa)
- Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion, cc-by-nc-nd)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Viral Infectious Diseases and Gene Expression in Insects
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein purification and stability
- Keywords
- monoclonal antibodies, cell engineering, mammalian cell expression systems, expression vector design, transfection, clone selection, antibody productivity, biopharmaceutical manufacturing, cell growth
- MeSH terms
- Animals, Antibodies, Monoclonal, Biotechnology, Humans, Technology, Pharmaceutical, Transfection, Protein Engineering, Cell Culture Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
